On Dec. 15, 2020, Inovio Pharma announced the company and a team of scientists from The Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University received a $37.6 million grant from the U.S. Defense Advanced Research Projects Agency (DARPA), part of the U.S. DoD to use INOVIO’s innovative DNA-encoded monoclonal antibody (dMAbﾮ) technology to develop anti-SARS-CoV-2-specific dMAbs which could offer versatile capabilities to function as both a therapeutic and preventive treatment for COVID-19.